Nephrology

ULTOMIRIS: A Complement Inhibitor for Treating Adult Patients with PNH - Drug Insights and Market Forecasts to 2032 with Focus on 7MM - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Research, Immune system, Hematology, Clinical trial, PNH, Patient, Neurology, SWOT, EU4, Hemolysis, Nephrology, Complement component 5, C5a, Inflammation, Risk management, Vaccine, Pharmaceutical industry

This report provides comprehensive insights about ULTOMIRIS for paroxysmal nocturnal hemoglobinuria (PNH) in the seven major markets.

Key Points: 
  • This report provides comprehensive insights about ULTOMIRIS for paroxysmal nocturnal hemoglobinuria (PNH) in the seven major markets.
  • The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities.
  • Further, it also consists of future market assessments inclusive of the ULTOMIRIS market forecast analysis for PNH in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PNH.
  • ULTOMIRIS is a complement inhibitor for treating adult patients with PNH.

CORE Kidney Unveils 2024 Rose Parade® Float - A Tribute to the Kidney Donors Who Gifted a Part of Themselves to Save a Life

Retrieved on: 
Tuesday, November 28, 2023
Other Philanthropy, Managed Care, General Health, Health, Philanthropy, Fund Raising, Foundation, Other Health, Kidney disease, Disease, Insurance, Patient, Multimedia, CORE, Kidney, Butterfly, Nephrology, Lupus nephritis, Rose Parade, Death, UCLA Health, Education, Family, Symbolism, Knowledge, Neuropsychology, Professor, Life, Transport, Pharmaceutical industry

CORE Kidney’s mission is to bring light to how widespread kidney disease is, with the goal of inspiring more people to take preventive measures.

Key Points: 
  • CORE Kidney’s mission is to bring light to how widespread kidney disease is, with the goal of inspiring more people to take preventive measures.
  • CORE Kidney is sending a direct message to the donors across the world to honor their courageous journey.
  • “To all the living kidney donors around the world, CORE is humbled by your life saving donation.
  • Green ribbon: a symbol of kidney health — a call back to the Green Ribbon Campaign started in 2016 by CORE Kidney that raised awareness for kidney health.

Children’s Hospital Los Angeles Recognized as National Surgical Quality Partner by American College of Surgeons

Retrieved on: 
Tuesday, November 21, 2023
Nursing, Managed Care, Teens, Surgery, Health, Children, Hospitals, Consumer, Digestive system surgery, Children's Hospital Los Angeles, Senior, Anesthesia, Trauma, Cardiology, ACS, SQP, Trauma Center, Patient, Multimedia, FAAP, Division, American College, FACS, Master of Science, News, MBA, MD, Nursing care plan, CHLA, Pediatric surgery, American College of Surgeons, Dentistry, Management, Orthopedic surgery, Surgeon, Urology, Neonatology, Nephrology

Children’s Hospital Los Angeles (CHLA) has been recognized as a National Surgical Quality Partner (SQP) by the American College of Surgeons (ACS) for its long-standing dedication to the highest standards in surgical patient care.

Key Points: 
  • Children’s Hospital Los Angeles (CHLA) has been recognized as a National Surgical Quality Partner (SQP) by the American College of Surgeons (ACS) for its long-standing dedication to the highest standards in surgical patient care.
  • View the full release here: https://www.businesswire.com/news/home/20231121829446/en/
    Children’s Hospital Los Angeles leadership and team members gather in front of the newly installed American College of Surgeons Surgical Quality Partner plaque.
  • The SQP designation lets patients know that Children’s Hospital Los Angeles is dedicated to relentless self-improvement and has been verified through a detailed and rigorous review from ACS.
  • “We are immensely proud to be named an ACS Surgical Quality Partner,” said James Stein, MD, MSc, FACS, FAAP, Senior Vice President and Chief Medical Officer at Children’s Hospital Los Angeles.

Kidneylink Announces Program Growth in Value-Based Kidney Care

Retrieved on: 
Wednesday, December 13, 2023
NPS, Chronic kidney disease, Kidney disease, Associate, ESKD, Pharmacist, Risk, RNS, Patient, Nephrology, USRC, Dialysis, CKD, Kidney transplantation, MD, Partnership, Social, Growth, Physician, FASN, Quality of life, Hospital, HIV disease progression rates, Pharmaceutical industry, Nursing

PLANO, Texas, Dec. 13, 2023 /PRNewswire/ -- Kidneylink – a national, value-based kidney care company founded by U.S. Renal Care, is pleased to announce significant growth and success on behalf of its patients and providers – expanding its network to more than 600 nephrologists across 20 U.S. based markets and caring for more than 16,000 people living with kidney disease, both Chronic Kidney Disease (CKD) and End Stage Kidney Disease (ESKD). Since its inception in 2021, Kidneylink has improved clinical outcomes for patients resulting in double-digit percentage reductions in hospitalizations and medical costs.

Key Points: 
  • PLANO, Texas, Dec. 13, 2023 /PRNewswire/ -- Kidneylink – a national, value-based kidney care company founded by U.S. Renal Care , is pleased to announce significant growth and success on behalf of its patients and providers – expanding its network to more than 600 nephrologists across 20 U.S. based markets and caring for more than 16,000 people living with kidney disease, both Chronic Kidney Disease (CKD) and End Stage Kidney Disease (ESKD).
  • Kidneylink is also not limited to U.S. Renal Care dialysis centers—more than 50% of Kidneylink ESKD patients are treated outside of USRC's facilities.
  • Many value-based kidney organizations rely on virtual care management teams that work around the nephrologist.
  • The future of kidney care is value-based care.

Boston Medical Center to Offer First FDA-Approved Gene Therapy Treatment Program for Sickle Cell Disease

Retrieved on: 
Friday, December 8, 2023
BMC, Safety, Chronic pain, Life, Pulmonology, CRISPR Therapeutics, Therapy, Sickle cell disease, Disease, Risk, Vertex Pharmaceuticals, Clinical trial, Vertex, Patient, Nephrology, End organ damage, FDA, Conditional sentence, DSM-IV codes, CRISPR, Pain, Doctor of Philosophy, Volatile organic compound, SCD, Stroke, Blood, Boston Medical Center, Center of excellence, Pharmaceutical industry, Nursing, MD

BOSTON, Dec. 8, 2023 /PRNewswire/ -- Boston Medical Center (BMC), a national leader in the treatment of sickle cell disease for more than 50 years, announced today that it will offer the first-ever gene therapy treatment program for sickle cell disease that uses a type of novel genome editing technology. The new therapy leverages the latest advances in medical science to alleviate the severe painful vaso-occlusive crises (VOCs) associated with sickle cell disease, in a long-awaited step toward equity for a disproportionally impacted Black patient population.

Key Points: 
  • BOSTON, Dec. 8, 2023 /PRNewswire/ -- Boston Medical Center (BMC), a national leader in the treatment of sickle cell disease for more than 50 years, announced today that it will offer the first-ever gene therapy treatment program for sickle cell disease that uses a type of novel genome editing technology.
  • The announcement comes as the FDA today granted approval of this new therapy, jointly developed by Boston-based Vertex Pharmaceuticals and CRISPR Therapeutics of Switzerland, along with approval of another cell-based gene therapy for sickle cell disease.
  • BMC is the only hospital in New England to offer the Vertex Pharmaceuticals and CRISPR Therapeutics therapy to eligible adults with sickle cell disease.
  • "Boston Medical Center has a longstanding commitment to providing advanced clinical care to those with sickle cell disease," said Dr. Jean-Antoine Ribeil, MD, PhD, Clinical Director of the Center of Excellence in Sickle Cell Disease at Boston Medical Center and an internationally renowned hematologist who has dedicated his career to the development of gene therapies for patients with sickle cell disease and beta thalassemia.

Joe DiMaggio Children's Hospital Now Offers More Children's Healthcare Services on Memorial Hospital Miramar Campus

Retrieved on: 
Wednesday, December 6, 2023
Otorhinolaryngology, Genetics, Sports medicine, Cardiology, Endocrinology, Elective surgery, Multimedia, Neurology, Memorial Hermann Health System, Nephrology, Health, Rehabilitation, ENT, Office, Hospital, General surgery, Allergy, Ferhat Ozcep

MIRAMAR, Fla., Dec. 6, 2023 /PRNewswire-PRWeb/ -- In a significant move aimed at enhancing children's healthcare services in the southwest Broward County, Joe DiMaggio Children's Hospital has expanded its world-class specialty care at Memorial Hospital Miramar. This expansion includes a broader range of services, such as allergy and immunology, cardiology, complex gastroenterology, genetics, otolaryngology (ENT), physical medicine and rehabilitation.

Key Points: 
  • In a significant move aimed at enhancing children's healthcare services in the southwest Broward County, Joe DiMaggio Children's Hospital has expanded its world-class specialty care at Memorial Hospital Miramar.
  • MIRAMAR, Fla., Dec. 6, 2023 /PRNewswire-PRWeb/ -- In a significant move aimed at enhancing children's healthcare services in the southwest Broward County, Joe DiMaggio Children's Hospital has expanded its world-class specialty care at Memorial Hospital Miramar .
  • Joe DiMaggio Children's Hospital is expanding its team of healthcare professionals at the Miramar location to better serve its diverse range of specialties.
  • Moreover, the hospital offers a variety of children's services, such as bone density testing, EEGs, imaging, lab services, and outpatient therapy.

Key Legislation (H.R. 3674) Considered During House Energy and Commerce Committee Markup

Retrieved on: 
Thursday, November 30, 2023
Kidney disease, RVU, Policy, USPA, Risk, Peripheral artery disease, Patient, Nephrology, Congress, Energy, Specialist, CMS, Cancer, Retirement, Urology, Medicare, Way, Physician, Ways and means committee, Legislation, Radiation, Hospital, Pharmaceutical industry, Health insurance, Nursing

WASHINGTON, Nov. 29, 2023 /PRNewswire-PRWeb/ -- The Providing Relief and Stability for Medicare Patients Act of 2023 (H.R. 3674), legislation to strengthen community and office-based providers, was considered during the Energy and Commerce Health Subcommittee markup held on November 15.

Key Points: 
  • 3674) , legislation to strengthen community and office-based providers, was considered during the Energy and Commerce Health Subcommittee markup held on November 15.
  • 3674 is bipartisan legislation that aims to stop ongoing cuts to office-based specialists for the next two years.
  • I hope that my colleagues agree to work on this legislation and to land on a path forward that supports access to community care.
  • Failing to do so will contribute to already shocking rates of physician shortages and reduces access to care for patients.

Prytime Medical Devices, Inc. Announces Appointment of Donna Syracuse as Chief Commercialization Officer

Retrieved on: 
Tuesday, November 21, 2023
SAN, Commercial, Cardiology, Intervention, Merit, Moyamoya disease, RN, Drainage, Patient, Dialysis, Region, Electrophysiology, NCTH, Nephrology, REBOA, Standard of care, Bleeding, Nursing care plan, Death, Growth, Hospital, Physician, Syracuse, Nursing, Angiography, Biopsy

SAN ANTONIO, Nov. 21, 2023 /PRNewswire-PRWeb/ -- Prytime Medical Devices Inc, The REBOA Company™, the leading innovator and global provider of lifesaving REBOA products for noncompressible torso hemorrhage (NCTH), announced that Donna Syracuse, RN, has joined the company as Chief Commercialization Officer effective August 28, 2023.

Key Points: 
  • Donna Syracuse has over 25 years of Commercial and Nursing Leadership in critical care, nephrology, cardiology, peripheral vascular disease, and electrophysiology.
  • Focused on clinical outcomes and evidence development, Donna was key in developing the HeRO® Graft market from launch to becoming Standard of Care for dialysis patients.
  • "I'm excited to join Prytime Medical at this point of its growth," said Donna.
  • "Donna's experience fits perfectly with Prytime's strategic goal for building outcomes-driven REBOA programs," said David Spencer, Prytime Medical CEO.

Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT

Retrieved on: 
Tuesday, November 14, 2023
Food, Therapy, Cardiology, IND, Sponsor, PMO, Patient, Agency, FDA, Messenger, Nephrology, Mastocytosis, Hoth, Cancer, Drug development, Pharmaceutical industry, Endocrinology, Hematology

NEW YORK, Nov. 14, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today the successful completion of a pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for its HT-KIT therapeutic. The Pre-IND meeting was completed through written responses provided by the FDA Nonmalignant Hematology Division of Regulatory Operations for Cardiology, Hematology, Endocrinology, and Nephrology.

Key Points: 
  • NEW YORK, Nov. 14, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today the successful completion of a pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for its HT-KIT therapeutic.
  • The Pre-IND meeting was completed through written responses provided by the FDA Nonmalignant Hematology Division of Regulatory Operations for Cardiology, Hematology, Endocrinology, and Nephrology.
  • Hoth Therapeutics, Inc., is developing the drug product HT-KIT indicated for the treatment of adult patients with AdvSM.
  • "We are very pleased with the outcome of the pre-IND meeting written responses from the FDA," said Robb Knie, CEO of Hoth Therapeutics.

EQS-News: Evotec enters partnership with Charité to expand molecular patient database in autoimmune diseases

Retrieved on: 
Thursday, December 14, 2023
EVO, B cell, Proteomics, Anti-neutrophil cytoplasmic antibody, Disease, Research, Inflammation, Partnership, Metabolomics, ISIN, AAV, Patient, Genomics, MDAX, Collection, ANCA, Database, Nephrology, Principal, Frankfurt Stock Exchange, Therapy, Blood, Pharmaceutical industry, Medical imaging, Evotec

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered a partnership with Charité Universitätsmedizin Berlin (“Charité”), one of the leading and largest university hospitals in Europe, to generate a molecular patient database for ANCA-associated vasculitis (“AAV”), a collection of relatively rare autoimmune diseases of unknown cause, characterised by inflammation of blood vessels.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered a partnership with Charité Universitätsmedizin Berlin (“Charité”), one of the leading and largest university hospitals in Europe, to generate a molecular patient database for ANCA-associated vasculitis (“AAV”), a collection of relatively rare autoimmune diseases of unknown cause, characterised by inflammation of blood vessels.
  • The strategic partnership between Evotec and Charité aims at achieving a better disease understanding of AAV by creating a unique longitudinal PanOmics database from the analysis of patient material.
  • Together with supplementary pseudonymised patient data, these PanOmics data will feed into Evotec’s proprietary translational molecular patient data platform E.MPD, which serves as the central data repository for molecular patient data.
  • Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are delighted to announce this exciting new partnership with Charité, a renowned centre of medical excellence in Germany, and expand Evotec’s E.MPD database within autoimmune diseases.